Low-pH Masked Antibody Formulations for Aggregation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Protein-based pharmaceuticals, such as antibodies, are prone to chemical and physical degradation, particularly aggregation, which affects stability and biological activity, and current methods to minimize aggregation are inefficient and yield-reducing.
Innovation Solution
A low pH pharmaceutical composition comprising a masked antigen binding protein with a masking domain and a protein recognition site, along with buffer agents and polyols, stabilizes the protein by electrostatic repulsion, reducing aggregation and denaturation during formulation, storage, and administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein pharmaceuticals are formulated at neutral pH and standard storage conditions, then biological activity is maintained, but aggregation and physical degradation occur rapidly
Solution Approach 1:
The patent applies parameter changes by formulating the protein pharmaceutical at acidic pH (pH 3-6, preferably pH 4-5) instead of the conventional neutral pH. This pH parameter change creates electrostatic repulsion between protein molecules, preventing aggregation and physical degradation while maintaining biological activity. The low pH formulation fundamentally alters the electrostatic environment to stabilize the protein composition.
2Reliability
If aggregation occurs during production and storage, then purification steps are required to remove aggregates, but this results in substantial yield loss and increased process complexity
Solution Approach 1:
The patent applies preliminary anti-action by preventing aggregation in the first place through acidic pH formulation and the use of masking proteins. Instead of allowing aggregates to form and then removing them through purification steps, the formulation conditions are designed to proactively prevent aggregate formation during production, storage, and handling. This eliminates the need for elaborate purification steps and preserves product yield.
3Stability of the object's composition
If genetic engineering is used to modify protein structure to increase interior hydrophobicity, then aggregation resistance may improve, but functionality is impaired and immunogenicity increases
Solution Approach 1:
The patent introduces masking proteins as intermediaries that bind to the protein pharmaceutical and prevent aggregation without requiring modification of the protein's primary structure. The masking proteins act as mediators that provide aggregation resistance through electrostatic repulsion at acidic pH, while the native protein structure and biological functionality remain intact. This intermediary approach avoids the trade-offs of genetic engineering.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly reduces antibody aggregation and high-molecular weight species, maintaining stability and functionality, with formulations showing up to 10-fold reduction in aggregation compared to reference compositions.
Implementation Method 1
stabilizes the protein by electrostatic repulsion, reducing aggregation and denaturation during formulation, storage, and administration
Data Source
AI summary
The present disclosure is directed to low pH pharmaceutical compositions and/or formulations comprising a masked antigen binding protein.